Cancer survival: Global surveillance will stimulate health policy and improve equity

The Lancet

Volumn 383, Issue 9916, 2014, Pages 564-573

  Coleman, Michel P ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER CONTROL; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; COMPARATIVE EFFECTIVENESS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; ECONOMIC DEVELOPMENT; ETHNIC GROUP; GENERAL PRACTITIONER; GROSS NATIONAL PRODUCT; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HUMAN; MORBIDITY; OVERALL SURVIVAL; POPULATION SIZE; PREMATURE MORTALITY; PRIMARY PREVENTION; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; PRODUCTIVITY; PUBLIC HEALTH; QUALITY CONTROL; SOCIAL STATUS; SOCIAL WORK; SURVIVAL RATE; SYSTEMATIC REVIEW (TOPIC); UNEMPLOYMENT;

EID: 84895900432     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)62225-4     Document Type: Review

References (90)

1. United Nations. Political declaration of the High-level Meeting of the General Assembly on the Prevention and Control of Non-communicable Diseases. A/66/L.1. http://www.who.int/nmh/events/un-ncd-summit2011/en/ (accessed Nov 14, 2013).
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
3. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2013; 380: 2095-128.
4. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol 2012; 13: 790-801.
5. World Health Organization. Report of the Formal Meeting of Member States to conclude the work on the comprehensive global monitoring framework, including indicators, and a set of voluntary global targets for the prevention and control of noncommunicable diseases. Geneva: WHO, Nov 21, 2012. http://who.int/gb/NCDs/pdf/A-NCD-2-en.pdf (accessed Nov 14, 2013).
6. World Health Organization. Assessing national capacity for the prevention and control of noncommunicable diseases: report of the 2010 global survey. Geneva: WHO, 2013. www.who.int/chp/knowledge/national-prevention-ncds/en/ (accessed Nov 14, 2013).
7. Parkin DM. The evolution of the population-based cancer registry. Nat Rev Cancer 2006; 6: 603-12.
8. O'Callaghan T. Introduction: the prevention agenda. Nature 2011; 471: S2-S4.
9. Brawley OW, Goldberg P. How we do harm: a doctor breaks ranks about being sick in America. New York: St Martin's Press, 2012.
10. Eckhouse S, Sullivan R. A survey of public funding of cancer research in the European Union. PLoS Med 2006; 3: e267. http://plosmedicine.org/article/ info%3Adoi%2F10.1371%2Fjournal.pmed/0030267 (accessed Dec 10, 2013).
11. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2013; 380: 2163-96.
12. Feachem RG, Sekhri NK, White KL. Getting more for their dollar: a comparison of the NHS with California's Kaiser Permanente. BMJ 2002; 324: 135-41.
13. Knaul FM, Arreola-Ornelas H, Atun R, et al. Investing in cancer care and control. In: Knaul FM, Gralow J, Atun R, Bhadelia A, eds. Closing the cancer divide: an equity imperative. Boston: Harvard University Press, 2011: 71-91.
14. Cavalli F. An appeal to world leaders: stop cancer now. Lancet 2013; 381: 425-26.
15. Sullivan R, Peppercorn J, Sikora K, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol 2011; 12: 933-80.
16. Keating N, Kouri E, Gralow JR, et al. Evidence for decision-making: stregthening health information systems and the research base. In: Knaul FM, Gralow J, Atun R, Bhadelia A, eds. Closing the cancer divide: an equity imperative. Boston: Harvard University Press, 2011: 289-310.
17. Union for International Cancer Control. World Cancer Declaration. UICC 2010. http://www.uicc.org/declaration/world-cancer-declaration (accessed Nov 14, 2013).
18. International Atomic Energy Agency. Inequity in cancer care: a global perspective. IAEA Human Health Reports No. 3. Vienna: IAEA, 2011.
19. Allemani C, Storm H, Voogd AC, et al. Variation in 'standard care' for breast cancer across Europe: a EUROCARE-3 high resolution study. Eur J Cancer 2010; 46: 1528-36
20. Micheli A, Coebergh JWW, Mugno E, et al. European health systems and cancer care. Ann Oncol 2003; 14 (suppl 5): 41-60.
21. Mostert S, Arora RS, Arreola M, et al. Abandonment of treatment for childhood cancer: position statement of a SIOP PODC Working Group. Lancet Oncol 2011; 12: 719-20.
22. Coleman MP, Quaresma M, Berrino F, et al, and the CONCORD Working Group. Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol 2008; 9: 730-56.
23. Woods LM, Rachet B, Coleman MP. Origins of socio-economic inequalities in cancer survival: a review. Ann Oncol 2006; 17: 5-19.
24. Roetzheim RG, Pal N, Gonzalez EC, Ferrante JM, Van Durme DJ, Krischer JP. Effects of health insurance and race on colorectal cancer treatments and outcomes. Am J Public Health 2000; 90: 1746-54.
25. Halpern MT, Ward EM, Pavluck AL, et al. Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis. Lancet Oncol 2008; 9: 222-31.
26. Editorial. Obama: health-care reform, part two. Lancet Oncol 2012; 13: 1171.
27. Sankaranarayanan R, Swaminathan R, Brenner H, et al. Cancer survival in Africa, Asia, and Central America: a population-based study. Lancet Oncol 2010; 11: 165-73.
28. Farmer P, Frenk J, Knaul FM, et al. Expansion of cancer care and control in countries of low and middle income: a call to action. Lancet 2010; 376: 1186-93.
29. Sikora K, Advani S, Koroltchouk V, et al. Essential drugs for cancer therapy: a World Health Organization consultation. Ann Oncol 1999; 10: 385-90.
30. Baili P, Micheli A, De Angelis R, et al, and the CONCORD Working Group. Life tables for world-wide comparison of relative survival for cancer (CONCORD study). Tumori 2008; 94: 658-68.
31. Corazziari I, Quinn MJ, Capocaccia R. Standard cancer patient population for age standardising survival ratios. Eur J Cancer 2004; 40: 2307-16.
32. Cookson JB. Cancer survival. Lancet 2000; 356: 1611.
33. Autier P, Boniol M, Héry C, Masuyer E, Ferlay J. Cancer survival statistics should be viewed with caution. Lancet Oncol 2007; 8: 1050-52, author reply 1053-54.
34. Beral V, Peto R. UK cancer survival statistics. BMJ 2010; 341: c4112. http://www.bmj.com/content/341/bmj.c4112.short (accessed Dec 10, 2013).
35. Woods LM, Coleman MP, Lawrence G, Rashbass J, Berrino F, Rachet B. Evidence against the proposition that "UK cancer survival statistics are misleading": simulation study with National Cancer Registry data. BMJ 2011; 342: d3399.
36. Beniaiche K. La déficience de notre système de santé est à l'origine du taux de survie si bas [in French]. El Watan [Algeria]. Nov 30, 2012, http://www.elwatan.dz/actualite/la-deficience-de-notre- systeme-de-sante-est-a-l-origine-du-taux-de-survie-si-bas-30-11-2012-194147-109. php (accessed Jan 5, 2013).
37. Perez-Saldivar ML, Fajardo-Gutierrez A, Bernaldez-Rios R, et al. Childhood acute leukemias are frequent in Mexico City: descriptive epidemiology. BMC Cancer 2011; 11: 355
38. Muñoz Hernández O, Cortés Gallo G, Garduño Espinosa J, et al. Informe final: análisis de los factores asociados a la variabilidad de los resultados en salud y costs del proceso de atención de cáncer en niños (leucemia linfoblástica aguda y linfoma de Hodgkin). Mexico City: Hospital Infantil de México Federico Gómez y Salud Seguro Popular, 2011.
39. Perez-Cuevas R, Doubova SV, Zapata Tarrés M, et al. Scaling up cancer care for children without medical insurance in developing countries: the case of Mexico. Pediatr Blood Cancer 2013; 60: 196-203.
40. Rivera-Luna R, Correa-Gonzalez C, Tamirano-Alvarez E, et al. Incidence of childhood cancer among Mexican children registered under a public medical insurance program. Int J Cancer 2013; 132: 1646-50.
41. Berrino F, Capocaccia R, Estève J, et al, eds. Survival of cancer patients in Europe: the EUROCARE-2 study (IARC Scientific Publications No. 151). Lyon: International Agency for Research on Cancer, 1999.
42. Ministry of Health. Piano Sanitario Nazionale 2001-2003 [in Italian]. Rome, Ministry of Health, 2001.
43. Coleman MP, Forman D, Bryant H, et al, and the ICBP Module 1 Working Group. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 2011; 377: 127-38.
44. Maringe C, Walters S, Rachet B, et al, and the ICBP Module 1 Working Group. Stage at diagnosis and colorectal cancer survival in six high-income countries: a population-based study of patients diagnosed during 2000-2007. Acta Oncol 2013; 52: 919-32.
45. Department of Health. NHS Outcomes Framework 2012-13. London: Department of Health, 2011.
46. Abdel-Rahman MA, Stockton DL, Rachet B, Hakulinen T, Coleman MP. What if cancer survival in Britain were the same as in Europe: how many deaths are avoidable? Br J Cancer 2009; 101 (suppl 2): S115-24.
47. Berrino F, De Angelis R, Sant M, et al, and the EUROCARE Working Group. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncol 2007; 8: 773-83.
48. Walters S, Maringe C, Butler J, Brierley JD, Rachet B, Coleman MP. Comparability of stage data in cancer registries in six countries: lessons from the International Cancer Benchmarking Partnership. Int J Cancer 2013; 132: 676-85.
49. Forbes LJ, Simon AE, Warburton F, et al. Differences in cancer awareness and beliefs between Australia, Canada, Denmark, Norway, Sweden and the UK (the International Cancer Benchmarking Partnership): do they contribute to differences in cancer survival? Br J Cancer 2013; 108: 292-300.
50. Allemani C, Sant M, Weir HK, et al. Breast cancer survival in the US and Europe: a CONCORD high-resolution study. Int J Cancer 2013; 132: 1170-81.
51. Department of Health. The NHS Cancer Plan: a plan for investment, a plan for reform. London: Department of Health, 2000.
52. Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R, and the EUROCARE Working Group. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999: results and commentary. Eur J Cancer 2009; 45 (suppl 6): 931-91.
53. Coleman MP, Alexe DM, Albreht T, et al, eds. Responding to the challenge of cancer in Europe. Ljubljana: Institute of Public Health of the Republic of Slovenia, 2008.
54. Commission of the European Communities. Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions on Action against Cancer: European Partnership. http://ec.europa.eu/health/ph-information/dissemination/diseases/ docs/com-2009-291.en.pdf (accessed Nov 14, 2013).
55. Karanikolos M, Ellis L, Coleman MP, McKee M. Health systems performance and cancer outcomes. J Natl Cancer Inst Monogr 2013; 46: 7-12.
56. Jansen L, Gondos A, Eberle A et al. Cancer survival in Eastern and Western Germany after the fall of the iron curtain. Eur J Epidemiol 2012; 27: 689-93.
57. Aareleid T, Brenner H. Trends in cancer patient survival in Estonia before and after the transition from a Soviet republic to an open-market economy. Int J Cancer 2002; 102: 45-50.
58. Verdecchia A, Francisci S, Brenner H, et al, and the EUROCARE-4 Working Group. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 2007; 8: 784-96.
59. Department of Health. Improving outcomes: a strategy for cancer. London: Department of Health, 2011.
60. Rachet B, Maringe C, Nur U, et al. Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England. Lancet Oncol 2009; 10: 351-69.
61. Storm HH, Gislum M, Engholm G. [Cancer survival before and after initiating the Danish Cancer Control plan] [In Danish, English abstract]. Ugeskr Læger [Danish Medical Journal] 2008; 170: 3065-69.
62. Rachet B, Ellis L, Maringe C, et al. Socioeconomic inequalities in cancer survival in England after the NHS cancer plan. Br J Cancer 2010; 103: 446-53.
63. Philipson T, Eber M, Lakdawalla DN, et al. An analysis of whether higher health care spending in the United States versus Europe is 'worth it' in the case of cancer. Health Aff (Millwood) 2012; 31: 667-75.
64. Brawley OW, Freeman HP. Race and outcomes: is this the end of the beginning for minority health research? J Natl Cancer Inst 1999; 91: 1908-09.
65. Rachet B, Woods LM, Mitry E, et al. Cancer survival in England and Wales at the end of the 20th century. Br J Cancer 2008; 99 (suppl 1): S2-10.
66. Brawley OW. Disaggregating the effects of race and poverty on breast cancer outcomes. J Natl Cancer Inst 2002; 94: 471-73.
67. Morrell S, You H, Baker D. Estimates of cancer incidence, mortality and survival in aboriginal people from NSW, Australia. BMC Cancer 2012; 12: 168.
68. Jeffreys M, Stevanovic V, Tobias M, et al. Ethnic inequalities in cancer survival in New Zealand: linkage study. Am J Public Health 2005; 95: 834-37.
69. Vedsted P, Olesen F. Are the serious problems in cancer survival partly rooted in gatekeeper principles? An ecologic study. Br J Gen Pract 2011; 61: e508-12.
70. Richards MA. The size of the prize for earlier diagnosis of cancer in England. Br J Cancer 2009; 101 (suppl 2): S125-29.
71. Department of Health. Improving outcomes: a strategy for cancer-second annual report 2012. London: Department of Health, 2012.
72. Richards MA, Stockton DL, Babb P, Coleman MP. How many deaths have been avoided through improvements in cancer survival? BMJ 2000; 320: 895-98.
73. Pokhrel A, Martikainen P, Pukkala E, Rautalahti M, Seppä K, Hakulinen T. Education, survival and avoidable deaths in cancer patients in Finland. Br J Cancer 2010; 103: 1109-14.
74. Dickman PW, Gibberd RW, Hakulinen T. Estimating potential savings in cancer deaths by eliminating regional and social class variation in cancer survival in the Nordic countries. J Epidemiol Community Health 1997; 51: 289-98.
75. Berrino F, Capocaccia R. Survival of European cancer patients. In: Coleman MP, Alexe DM, Albreht T, McKee CM, eds. Responding to the challenge of cancer in Europe. Ljubljana: Institute of Public Health of the Republic of Slovenia, 2008: 151-76.
76. Kelly R. Cancer deaths. Commons Hansard [Parliamentary Record], London: HMSO, 2002: c703W-c704W, http://www.publications.parliament.uk/pa/cm200102/ cmhansrd/vo020311/text/20311w16.htm#20311w16.html-sbhd0 (accessed Dec 10, 2013).
77. Seppä K, Hakulinen T, Läärä E. Avoidable deaths and random variation in patients' survival. Br J Cancer 2012; 106: 1846-49.
78. Ellis L, Coleman MP, Rachet B. How many deaths would be avoidable if socioeconomic inequalities in cancer survival in England were eliminated? A national population-based study, 1996-2006. Eur J Cancer 2012; 48: 270-78.
79. Verdecchia A, De Angelis R, Capocaccia R, et al. The cure for colon cancer: results from the EUROCARE study. Int J Cancer 1998; 77: 322-29.
80. Francisci S, Capocaccia R, Grande E, et al, and the EUROCARE Working Group. The cure of cancer: a European perspective. Eur J Cancer 2009; 45: 1067-79.
81. Anderson BO, Cazap E, El Saghir NS, et al. Optimisation of breast cancer management in low-resource and middle-resource countries: executive summary of the Breast Health Global Initiative consensus, 2010. Lancet Oncol 2011; 12: 387-98.
82. Ferlay J, Parkin DM, Curado MP, et al. Cancer incidence in five continents, volumes I to IX: IARC CancerBase No. 9 [Internet]. http://ci5.iarc.fr (accessed Nov 14, 2013).
83. Sant M, Aareleid T, Berrino F, et al, and the EUROCARE Working Group. EUROCARE-3: survival of cancer patients diagnosed 1990-94-results and commentary. Ann Oncol 2003; 14 (suppl 5): 61-118.
84. Quaresma M, Coleman MP, Rachet B. Funnel plots for population-based cancer survival: principles, methods and applications. Stat Med 2013 Sep 4. DOI:10.1002/sim.5953. [Epub ahead of print]
85. Eloranta S, Adolfsson J, Lambert PC, et al. How can we make cancer survival statistics more useful for patients and clinicians: an illustration using localized prostate cancer in Sweden. Cancer Causes Control 2013; 24: 505-15.
86. World Bank. List of economies (18 July 2011). Washington DC: World Bank, 2011. http://data.worldbank.org/about/country-classifications/country-and- lending-groups (accessed Nov 14, 2013).
87. Extramural Committee to Assess Measures of Progress Against Cancer. Measurement of progress against cancer. J Natl Cancer Inst 1990; 82: 825-35.
88. Karim-Kos HE, de Vries E, Soerjomataram I, et al. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer 2008; 44: 1345-89.
89. Shah A, Stiller CA, Kenward MG, Vincent T, Eden TO, Coleman MP. Childhood leukaemia: long-term excess mortality and the proportion 'cured'. Br J Cancer 2008; 99: 219-23.
90. Chan M. Address to WHO staff. http://www.who.int/dg/speeches/2007/ address.to.staff/en/index.html (accessed Nov 14, 2013).